Cosentyx (secukinumab) is a biologic medication used to treat various inflammatory conditions such as psoriasis, psoriatic arthritis, and ankylosing spondylitis [1]. According to the sources provided, increasing the dosage of Cosentyx can lead to certain risks.

The recommended dosage of Cosentyx is 300mg administered as two subcutaneous injections of 150mg each at Weeks 0, 1, 2, 3, and 4 followed by a maintenance dose of 150mg every 4 weeks [2]. The maximum recommended dosage is 300mg per injection [3].

Increasing the dosage of Cosentyx beyond the recommended maximum dose can increase the risk of adverse effects such as infections, allergic reactions, and injection site reactions [3]. In addition, Cosentyx may increase the risk of developing tuberculosis, so it is important to screen patients for tuberculosis before starting treatment [1].

It is important to note that the risks associated with increasing the dosage of Cosentyx may vary depending on the individual patient's medical history, current health status, and other medications they may be taking. Therefore, patients should always consult with their healthcare provider before making any changes to their medication regimen.

In conclusion, increasing the dosage of Cosentyx beyond the recommended maximum dose can increase the risk of adverse effects such as infections, allergic reactions, and injection site reactions. Patients should always consult with their healthcare provider before making any changes to their medication regimen [3].

Sources:
[1] https://www.drugpatentwatch.com/p/biologics/tradename/COSENTYX
[2] https://www.cosentyx.com/psoriatic-arthritis/treatment-dosing
[3] https://reference.medscape.com/drug/cosentyx-secukinumab-999964